Shares of Xenon Pharmaceuticals (XENE) have gained approximately 20% over the past three months, primarily driven by positive top-line data from the X-TOLE2 study evaluating its lead candidate, ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Agent workflows make transport a first-order ...
Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more than 50% for some patients as it looks to position itself to become the ...
Xenon Pharmaceuticals Inc. XENE-Q stock soared Monday after the Canadian drug developer reported better-than-expected results from a late-stage human trial for its epilepsy treatment. Burnaby, ...
VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Connecticut-based Braidwell disclosed a sale of 1,779,953 shares of Xenon Pharmaceuticals (NASDAQ:XENE) in its February 17, 2026, SEC filing, an estimated $74.76 million trade based on quarterly ...
Connecticut-based Braidwell sold 1,779,953 Xenon Pharmaceuticals shares in the fourth quarter; the estimated transaction value was $74.76 million based on quarterly average prices. Meanwhile, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results